News

MM&M11d
Dupixent tops pharma ad impressions rankings for Q1 2025
Dupixent topped Rx and over-the-counter (OTC) pharma brands for ad impressions during Q1 2025, according to data released by iSpot.tv on Monday afternoon. The Regeneron and Sanofi brand for asthma and ...
Yahoo Finance7d
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
“Dupixent is the first new targeted treatment for chronic spontaneous urticaria, or CSU, in over ten years, with pivotal trials demonstrating its ability to help patients significantly reduce ...
Yahoo Finance6d
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and ...
manilatimes7d
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...
pharmaphorum2d
Sanofi's Dupixent gets FDA nod for chronic hives indication
Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria (CSU), a condition that causes painful hives that often don't respond to ...
Yahoo Finance6d
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
“The approval of this treatment offers patients more options and the chance to control their disease.” “Dupixent is the first new targeted treatment for chronic spontaneous urticaria, or CSU, in over ...